期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

血液透析患者骨保护素基因多态性与骨密度关系的研究 被引量：1

下载PDF
导出
摘要 目的探讨骨保护素基因(OPG)的基因多态性与血液透析患者骨密度(BMD)是否具有相关性。方法选择2009年6月至2010年6月湖南省某院肾内科维持性血液透析治疗患者112例为研究对象。采用MALDI-TOFMS技术检测患者OPG的基因多态性分布。结果 (1)血液透析患者rs11573928和rs2073618两个多态性位点在不同基因型之间BMD差异有统计学意义(P<0.05)。rs11573928位点AA型患者股骨颈BMD高于AG和GG型,rs2073618位点CC型患者腰椎BMD明显高于GC和GG型。(2)OPG基因rs2073618位点多态性是血液透析患者发生骨量减少和骨质疏松的相关变量(r=0.265,P=0.016)。结论 OPG基因rs11573928、rs2073618多态性与湖南长沙地区血液透析患者BMD具有相关性。
作者 肖海清 何计南
机构地区 湖南师范大学第一附属医院肾内科
出处 《重庆医学》 CAS CSCD 北大核心 2012年第10期983-985,共3页 Chongqing medicine
基金 湖南省医药卫生科研计划课题基金项目(B2007138)
关键词 肾透析 骨保护素 多态性 单核苷酸 骨密度 MALDI-TOFMS
分类号 R580 [医药卫生—内分泌]
  • 相关文献

参考文献8

  • 1Bucay R,Sarosi I,Dunstan CR,et al.Osteoprotegerin-de-ficient mice develop early onsetosteoporosis and arterial calcification[J].Genes Dev,1998,12(9):1260-1268.
  • 2Simonet WS,Lacey DL,Dunstan CR,et al.Osteoprote-gerin:a novel secreted protein involved in the regulation of bone density[J].Cell,1997,89(2):309-319.
  • 3Langdahl BL,Carstens M,Stenkjaer L,et al.Polymor-phisms in the osteoprotegerin gene are associated with osteoporotic fractures[J].J Bone Miner Res,2002,17(7):1245-1255.
  • 4赵红燕,刘建民,宁光,宋怀东,陈瑛,张连珍,孙立昊,赵咏桔,许曼音,陈家伦.绝经后妇女护骨素基因G1181C多态性与骨密度变化相关[J].中华内分泌代谢杂志,2005,21(1):55-58. 被引量：10
  • 5Arko B,Prezelj J,Kocijancic A,et al.Association of the osteoprotegerin gene polymorphisms with bone mineral density in postmenopausal women[J].Maturitas,2005,51(3):270-279.
  • 6Ohmori H,Makita Y,Funamizu M,et al.Linkage and as-sociation analyses of the osteoprotegerin gene locus with human osteoporosis[J].J Hum Genet,2002,47(8):400-406.
  • 7Ueland T,Bollerslev J,Wilson SG,et al.No associations between OPG gene polymorphisms or serum levels and measures of osteoporosis in elderly Australian women[J].Bone,2007,40(1):175-181.
  • 8Vidal C,Brincat M,Xuereb Anastasi A.TNFRSF11Bgene variants and bone mineral density in postmenopaus-al women in Malta[J].Maturitas,2006,53(4):386-395.

二级参考文献16

  • 1Giguere Y, Rousseau F. The genetics of osteoporosis: 'complexities and difficulties'. Clin Genet, 2000,57:161-169.
  • 2Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev, 2000,21:115-137.
  • 3Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 1998,93:165-176.
  • 4Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA, 1999,96:3540-3545.
  • 5Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 1997,89:309-319.
  • 6Tsuda E, Goto M, Mochizuki S, et al. Isolation of a novel cytokin from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun, 1997,234:137-142.
  • 7Fuller K, Wong B, Fox S, et al. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med, 1998,188:997-1001.
  • 8Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin(OPGL) directly activates mature osteoclasts. J Cell Biol, 1999,145:527-538.
  • 9Mizuno A, Amizuka N, Irie K, et al. Severe oeteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun, 1998,247:610-615.
  • 10Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev, 1998,12:1260-1268.

共引文献9

同被引文献34

  • 1Simonet WS,Lacey DL,Dunstall CR,et al.Osteoprotegerin:a novel secreted protein involved in the regulation of bone density[J].Cell,1997,89(2):309.
  • 2Vidal C,Formosa R,Xuereb-Anastasi A.Functional polymorphisms within the TNFRSF11B(osteoprotegerin)gene increase the risk for low bone mineral density[J].Journal of Molecular Endocrinology,2011,47(3):327-333.
  • 3郏蓉,纪立农.老年人BMD与OPG基因启动子区SNPs及骨代谢生化指标的相关分析研究[D].2011年北京医学会内分泌暨糖尿病学分会学术年会论文集,2011:128-129.
  • 4Roshandel D,Holliday KL,Pye SR,et al.Influence of polymorphisms in the RANKL/RANK/OPG signaling pathway on volumetric bone mineral density and bone geometry at the forearm in men[J].Calcified Tissue International,2011,89(6):446-455.
  • 5Luo Y,Hu Z,Hao J,et al.Significant Associations Between the A163G and G1181C Polymorphisms of the Osteoprotegerin Gene and Risk of Osteoporosis,Especially in Postmenopausal Women:A Meta-Analysis[J].Genetic Testing and Molecular Biomarkers,2014,18(3):211-219.
  • 6Chao TH,Yu HN,Huang CC,et al.Opposite associations of osteoprotegerin and ZBTB40 polymorphisms with bone mineral density of the hip in postmenopausal Taiwan Residents women[J].Journal of the Chinese Medical Association,2012,75(7):335-340.
  • 7Zhang F,He C,Chen G,et al.Association analyses of osteoprotegerin gene polymorphisms withbone mineral density in Chinese postmenopausal women[J].Med Oncol,2013,30(1):389.
  • 8Shen L,Qiu Y,Xing S,et al.Association between osteoprotegerin genetic variants and bone mineral density in Chinese women[J].Int Immunopharmacol,2013,16(2):275-278.
  • 9Wang Q,Chen Z,Huang Y,et al.The relationship between osteoprotegerin gene polymorphisms and bone mineral density in Chinese postmenopausal women[J].Int Immunopharmacol,2013,17(2):404-407.
  • 10Takács I,Lazáryá,Kósa JP,et al.Allelic variations of RANKL/OPG signaling system are related to bone mineral density and in vivo gene expression[J].European Journal of Endocrinology,2010,162(2):423-431.

引证文献1

二级引证文献3

重庆医学
2012年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部